These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 27056998)
1. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998 [TBL] [Abstract][Full Text] [Related]
2. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756 [TBL] [Abstract][Full Text] [Related]
3. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. Song Z; Su H; Zhang Y Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. Bylicki O; Tomasini P; Radj G; Guisier F; Monnet I; Ricordel C; Bigay-Game L; Geier M; Chouaid C; Daniel C; Swalduz A; Toffart AC; Doubre H; Peloni JM; Moreau D; Subtil F; Grellard JM; Castera M; Clarisse B; Martins-Lavinas PH; Decroisette C; Greillier L; Eur J Cancer; 2023 Apr; 183():38-48. PubMed ID: 36801605 [TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. Camidge DR; Kono SA; Lu X; Okuyama S; BarĂ³n AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183 [TBL] [Abstract][Full Text] [Related]
6. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512 [TBL] [Abstract][Full Text] [Related]
7. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664 [TBL] [Abstract][Full Text] [Related]
8. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546 [TBL] [Abstract][Full Text] [Related]
9. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967 [TBL] [Abstract][Full Text] [Related]
10. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518 [TBL] [Abstract][Full Text] [Related]
11. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements? Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798 [TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866 [TBL] [Abstract][Full Text] [Related]
15. Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With Hubbeling H; Choudhury N; Flynn J; Zhang Z; Falcon C; Rusch VW; Park BJ; Ziv E; Shaverdian N; Gelblum DY; Shepherd AF; Simone CB; Wu AJ; Gomez DR; Drilon A; Rimner A JCO Precis Oncol; 2022 Oct; 6():e2200024. PubMed ID: 36201714 [TBL] [Abstract][Full Text] [Related]
16. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers. Wang Y; Zhang S; Wu F; Zhao J; Li X; Zhao C; Ren S; Zhou C BMC Cancer; 2018 Mar; 18(1):326. PubMed ID: 29587667 [TBL] [Abstract][Full Text] [Related]
18. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636 [TBL] [Abstract][Full Text] [Related]
19. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. Cha YJ; Kim HR; Shim HS J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]